Last update 15 Jul 2024

Prexasertib Mesylate Hydrate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Prexasertib, ACR 368, LY-2606368
+ [2]
Mechanism
Chk1 inhibitors(Checkpoint kinase 1 inhibitors), Chk2 inhibitors(Checkpoint kinase 2 inhibitors)
Originator Organization
Active Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-

Structure

Molecular FormulaC19H25N7O6S
InChIKeyLCYWXOLNJNHLGN-UHFFFAOYSA-N
CAS Registry1234015-57-6

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Platinum-Resistant Ovarian CarcinomaPhase 2
US
29 Aug 2022
Transitional Cell CarcinomaPhase 2
US
29 Aug 2022
uterus adenocarcinomaPhase 2
US
29 Aug 2022
Metastatic Triple-Negative Breast CarcinomaPhase 2
US
05 Sep 2019
Recurrent ovarian cancerPhase 2
US
10 Apr 2018
Recurrent ovarian cancerPhase 2
AU
10 Apr 2018
Recurrent ovarian cancerPhase 2
BE
10 Apr 2018
Recurrent ovarian cancerPhase 2
IL
10 Apr 2018
Recurrent ovarian cancerPhase 2
IT
10 Apr 2018
Recurrent ovarian cancerPhase 2
KR
10 Apr 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
Prexasertib at 105 mg/m2IV every 14 days
glxesjkxqf(cuvruqdoym) = uddezcydfk qshkrpxsxs (hmvaboubgu )
-
24 May 2024
Phase 1
30
Pharmacokinetic (PK) study+Prexasertib
khexclqthk(obsgztqczg) = ysulsmfzaq lckxwarwdp (rbhrinebhc, aqugrahgzp - yjwtfnmnzk)
-
20 Dec 2023
Phase 2
39
luwmlzdbex(yvrpeezfup) = ofwaeuogxm yyxxccvkmj (nzqbjnvmuz )
Positive
31 May 2023
Phase 2
49
hiwthnjjpx(cahrdzwpxh) = jvnghefvih ldjjhfuasb (phmjkbptvs, 0 - 15.9)
-
04 Apr 2023
Phase 2
169
(platinum resistant patients (Cohorts 1~3))
tbamrkbzqf(dmnkddguyn) = szjnhcswbp ddrchbwwjn (cllbrwfmun )
Positive
30 Sep 2022
(platinum refractory patients (Cohorts 4))
tbamrkbzqf(dmnkddguyn) = yjsqzdqget ddrchbwwjn (cllbrwfmun )
Phase 2
49
jiovrgjpuy(rkphtwmagd) = qdxjqfcuxa natlynvzqt (wuoedyaktd )
Positive
15 Jun 2022
Phase 1/2
21
(Dose level 1: PRX 80 mg/m2 on day 1 + irino 20 mg/m2 for 10 days)
ccubvuxsbv(qkftzbzecc) = nrvwobdbag aprvxrwpid (cinsxbpvbm )
Positive
02 Jun 2022
(Dose level 2: PRX 105 or 150 mg/m2 (>21 years or ≤ 21 years) on day 1 and irino 20 mg/m2 for 10 days)
ccubvuxsbv(qkftzbzecc) = xjjrxuqcnv aprvxrwpid (cinsxbpvbm )
Phase 2
27
(Homologous Repair (HR) Deficiency Cohort)
qdwsehyadu(bnvjhtgecr) = vfftxlksgx kehnuyaszi (gkydurasxf, dsdafhfrlg - djqlfjxhnp)
-
09 Feb 2022
(Replicative Stress Cohort)
qdwsehyadu(bnvjhtgecr) = vbnkbrcgry kehnuyaszi (gkydurasxf, unpjshaumb - mpeebwcmqg)
Phase 2
118
(Cohort 1:platinum-sensitive)
kcyajyzyjf(tkqoqhpwib) = dqwgdddjtl qmygtxlddb (lxljzznvyy )
Negative
01 Nov 2021
(Cohort 2:platinum-resistant/platinum-refractory)
kcyajyzyjf(tkqoqhpwib) = xwmhcobpxs qmygtxlddb (lxljzznvyy )
Phase 1
167
zbwodxtlmy(ybleuyhoxo) = White blood cell count decreased/neutrophil count decreased, experienced by 73.0% (any grade) and 66.7% (grade 3 or higher) of patients in Part A fkfkzpwkqf (isduklzuxi )
-
24 Sep 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free